Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data?

被引：2

作者：

Basaran, Gul ^{[1
]}

Agaoglu, Fulya ^{[2
]}

Basaran, Mert ^{[2
]}

机构：

[1] Marmara Univ Hosp, Istanbul, Turkey

[2] Istanbul Univ, Inst Oncol, Istanbul, Turkey

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 27期

关键词：

RADIATION-THERAPY; ABVD CHEMOTHERAPY; RADIOTHERAPY; DISEASE; TRIAL;

D O I：

10.1200/JCO.2010.29.0304

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：E485 / E486

页数：2

共 39 条

[1] Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Alone in Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma: Do We Really Have Robust Data? Reply
Canellos, George
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (27) : E487 - E487
[2] Balancing Risks and Benefits of Therapy for Patients with Favorable-Risk Limited-Stage Hodgkin Lymphoma: The Role of Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine Chemotherapy Alone
Hay, Annette E.
Meyer, Ralph M.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2014, 28 (01) : 49 - +
[3] Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma
Abramson, Jeremy S.
Amason, Jon E.
LaCasce, Ann S.
Redd, Robert
Barnes, Jeffrey A.
Sokol, Lubomir
Joyce, Robin
Avigan, David
Neuberg, Donna
Takvorian, Ronald W.
Hochberg, Ephraim P.
Bello, Celeste M.
BLOOD, 2019, 134 (07) : 606 - 613
[4] Brentuximab vedotin plus doxorubicin and dacarbazine in nonbulky limited-stage classical Hodgkin lymphoma
Abramson, Jeremy S.
Bengston, Elizabeth
Redd, Robert
Barnes, Jeffrey A.
Takvorian, Tak
Sokol, Lubomir
Lansigan, Frederick
Armand, Philippe
Shah, Bijal
Jacobsen, Eric
Martignetti, Rosalba
Turba, Elyce
Metzler, Sara
Patterson, Victoria
LaCasce, Ann S.
Bello, Celeste M.
BLOOD ADVANCES, 2023, 7 (07) : 1130 - 1136
[5] Sarcoidosis-like reaction after treatment with doxorubicin, bleomycin, vinblastine and dacarbazine in a patient with Hodgkin's lymphoma
Torrent, Anna
Tomas Navarro, Jose
Cristobal Andreo, Felipe
Ribera, Josep-Maria
MEDICINA CLINICA, 2013, 141 (03): : 134 - 135
[6] The Case for Chemotherapy Alone for Limited-Stage Hodgkin's Lymphoma
Connors, Joseph M.
ONCOLOGIST, 2012, 17 (08): : 1011 - 1013
[7] Treatment of Favorable, Limited-Stage Hodgkin's Lymphoma With Chemotherapy Without Consolidation by Radiation Therapy
Canellos, George P.
Abramson, Jeremy S.
Fisher, David C.
LaCasce, Ann S.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (09) : 1611 - 1615
[8] Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma
Xicoy, Blanca
Ribera, Josep-Maria
Miralles, Pilar
Berenguer, Juan
Rubio, Rafael
Mahillo, Beatriz
Valencia, Maria-Eulalia
Abella, Eugenia
Lopez-Guillermo, Armando
Sureda, Ana
Morgades, Mireia
Navarro, Jose-Tomas
Esteban, Herminia
Mate, J. L.
Cosin, J.
Lopez, J. C.
Pulido, F.
Moreno, V
Cepeda, C.
Gonzalez, J.
Tellez, M. J.
Vergas, J.
Estrada, V
Roca, V
Montes, M. L.
Arribas, J. R.
Gonzalez-Garcia, J.
Lacruz, J.
Lopez, J.
Salavert, M.
Santos, J.
Palacios, R.
Marquez, M.
Sepulveda, M. A.
de la Torre, A.
Rivero, A.
Garcia, M.
Pintado, V
Antela, A.
Patier, L.
Rodriguez, L., I
HAEMATOLOGICA, 2007, 92 (02) : 191 - 198
[9] Limited, But Not Eliminated, Excess Long-Term Morbidity in Stage I-IIA Hodgkin Lymphoma Treated With Doxorubicin, Bleomycin, Vinblastine, and Dacarbazine and Limited-Field Radiotherapy
Lagerlof, Ingemar
Fohlin, Helena
Enblad, Gunilla
Glimelius, Bengt
Goldkuhl, Christina
Palma, Marzia
Akesson, Lisa
Glimelius, Ingrid
Molin, Daniel
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (13) : 1487 - 1496
[10] Neutropenia and febrile neutropenia in patients with Hodgkin's lymphoma treated with doxorubicin (Adriamycin), bleomycin, vinblastine and dacarbazine (ABVD) chemotherapy
Chand, VK
Link, BK
Ritchie, JM
Shannon, M
Wooldridge, JE
LEUKEMIA & LYMPHOMA, 2006, 47 (04) : 657 - 663

← 1 2 3 4 →